ClinicalTrials.gg
CompletedNCT07608692Updated Jun 1, 2026

Comparative Clinical Trial of Pharmacokinetics and Pharmacodynamics of Human Insulin Injection

A Phase 1 interventional study of Human Insulin Injection(USLIN®R) and Human Insulin Injection(NOVOLIN®R) in Pharmacokinetics and Pharmacodynamics, sponsored by Zhuhai United Laboratories Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Zhuhai United Laboratories Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2025, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A study of Clinical Trial Comparing Pharmacokinetics and Pharmacodynamics of Human Insulin Injection,in Wuhan Pulmonary Hospital (Wuhan Tuberculosis Prevention and Control Institute).To compare the pharmacokinetic and pharmacodynamics properties of a single subcutaneous dose of the human insulin injection (USLIN®R, Zhuhai United Laboratories (Zhongshan) Co., Ltd.) with the reference product (Novolin®R, Novo Nordisk Inc.) in healthy male subjects,and to evaluate the safety, tolerability, and immunogenicity of the test formulation versus the reference formulation in healthy male subjects.This single-center, randomized, double-blind, two-formulation, single-dose, two-period crossover study will enroll 32 healthy male subjects randomized 1:1 into two sequence groups (A/B, group A is administered in the sequence of T-R, while group B is in R-T). To evaluate the pharmacokinetic and pharmacodynamic properties of the test preparation and the control preparation in healthy male subjects. Each subject will receive single doses of both test and reference formulations across two periods (with ≥14-day washout), following the predefined sequence allocation table. After completing period 2 pharmacokinetic blood sampling, subjects will administer assigned insulin TID for two consecutive days to assess test-reference immunogenicity differences.

02

Conditions studied

  • Pharmacokinetics and Pharmacodynamics
03

In context

Lead sponsor

Zhuhai United Laboratories Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 55 years old (inclusive of 18 and 55 years).
  2. Gender: Male.
  3. Body Weight: Not less than 55.0 kg for men, with a [BMI = weight (kg) / height² (m²)] between 18.0 and 29.0 kg/m² (inclusive of boundary values).
  4. Vital Signs: Systolic blood pressure ≥90 mmHg and \<140 mmHg, diastolic blood pressure ≥60 mmHg and \<90 mmHg, pulse rate ≥60 beats/min and ≤100 beats/min, body temperature (forehead) between 36.0°C and 37.3°C, with final judgment by the investigator.
  5. Glucose Tolerance: Normal glucose tolerance (fasting plasma glucose (FPG) \<6.10 mmol/L and >3.50 mmol/L, and 2-hour postprandial blood glucose in oral glucose tolerance test (OGTT) \<140 mg/dL (7.78 mmol/L)), value \<6.3% and >4.5%.

Exclusion criteria

Exclusion Criteria:

  1. Those who have participated in a clinical trial of another drug/device and used the drug/device within 6 months.
  2. Those with abnormal conditions requiring exclusion, including but not limited to neurological, cardiovascular, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal system disorders, particularly those with a history of hypoglycemia, hypokalemia, postural hypotension, syncope or blackout, diabetes mellitus, or a family history (first-degree relatives) of diabetes mellitus.
  3. Those with a history of severe vomiting, diarrhea, or any other disease or condition that could interfere with trial results within 7 days prior to the trial.
  4. Those with a history of specific allergies (e.g., asthma, urticaria, eczema) or allergies to any medications, foods, or pollen, or known allergies to insulin.
  5. Those with positive anti-insulin antibodies.
  6. Those who have lost or donated more than 400 mL of blood, received blood transfusions, or used blood products within 3 months prior to the trial, or who plan to donate blood during the trial.
  7. Subjects with plans for childbearing or sperm donation from 2 weeks prior to the trial to 6 months after the last dose, and who are unwilling or unable to use effective .
  8. Those with clinically significant abnormalities in general physical examination, laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, etc.) within 7 days prior to the trial, or results deemed clinically significant by the clinician within 14 days prior to the trial.
  9. Those with one or more clinically significant positive results for , , , or syphilis tests.
  10. Those who have undergone surgery within 3 months prior to the trial, plan to undergo surgery during the study, or have had surgery that affects drug absorption, distribution, metabolism, or excretion.
  11. Those who consumed more than 14 units of alcohol per week within 3 months prior to the trial (1 unit = 17.7 mL ethanol, i.e., 354 mL of 5% alcohol beer, 44 mL of 40% alcohol liquor, or 147 mL of 12% alcohol wine), or those unable to abstain from alcohol during the trial.
  12. Those who smoked an average of more than 5 cigarettes per day within 3 months prior to the trial, or those unable to stop using any tobacco-based or nicotine products (e.g., nicotine patches, chewing gums) during the trial.
  13. Those who consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, 1 cup = 250 mL) per day within 3 months prior to the trial.
  14. Those who consumed any food or beverage rich in caffeine/xanthine or other special ingredients (e.g., strong tea, coffee, chocolate, cola, animal offal, grapefruit, grapefruit juice, dragon fruit, mango) from screening to 2 days before admission, which, in the investigator's judgment, may affect drug absorption, distribution, metabolism, or excretion, or those unable to stop consuming such foods or beverages by the end of drug administration.
  15. Those who used any drugs that alter liver enzyme activity within 28 days prior to the trial (common liver enzyme inducers: barbiturates (phenobarbital being the most common), carbamazepine, aminoglutethimide, griseofulvin, meprobamate, phenytoin, glutethimide, rifampicin, dexamethasone; common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, sulfonamides).
  16. Those who used any drugs affecting insulin's glucose-lowering effects within 28 days prior to the trial (e.g., , danazol, diazoxide, diuretics, epinephrine, salbutamol, terbutaline, glucagon, growth hormone, thyroid hormone, beta-blockers).
  17. Those unable to eat, with swallowing difficulties, special dietary requirements, or unable to follow a standardized diet.
  18. Those who used any prescription drugs, over-the-counter drugs, nutraceuticals, herbal products, or vaccines within 14 days prior to the trial.
  19. Those engaged in hazardous mechanical operations, such as working at heights or driving motor vehicles.
  20. Those unable to tolerate venipuncture or with a history of hemophobia or needle phobia.
  21. Those with a history of asthma or seizures.
  22. Those with a history of hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
  23. ;Those who used any illicit drugs within one year prior to the trial.
  24. Those with a positive alcohol breath test or positive drug abuse screening.
  25. Subjects deemed by the investigator to have poor treatment compliance or any factors making participation in this trial inappropriate.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: Human Insulin Injection(USLIN®R) · Drug: Human Insulin Injection(NOVOLIN®R)

  • Active comparator
    Group B

    Drug: Human Insulin Injection(USLIN®R) · Drug: Human Insulin Injection(NOVOLIN®R)

Interventions

  • DrugHuman Insulin Injection(USLIN®R)

    a single subcutaneous dose of 0.3 IU/kg

  • DrugHuman Insulin Injection(NOVOLIN®R)

    a single subcutaneous dose of 0.3 IU/kg

06

What researchers measure

Primary outcomes

  1. Primary PK Parameters (Peak Plasma Concentration (Cmax))

    PK Parameters (Peak Plasma Concentration (Cmax))

    Time frame: 0 to 12 hours

  2. Primary PK Parameters (Area under the plasma concentration-time curve from time 0 to time τ(AUC0-τ))

    Area under the plasma concentration-time curve from time 0 to time τ(AUC0-τ)

    Time frame: 0 to 12 hours

  3. Primary PD Parameters (Area under the glucose infusion rate curve from time 0 to time τ(AUCGIR0-τ))

    Area under the glucose infusion rate curve from time 0 to time τ(AUCGIR0-τ)

    Time frame: 0 to 12 hours

  4. Primary PD Parameters (Maximum glucose infusion rate (GIRmax))

    Maximum glucose infusion rate (GIRmax)

    Time frame: 0 to 12 hours

Secondary outcomes

  1. Secondary PK Parameters (Area under the plasma concentration-time curve from time 0 to time 2 hours(AUC0-2h))

    Area under the plasma concentration-time curve from time 0 to time 2 hours(AUC0-2h)

    Time frame: 0 to 2 hours

  2. Secondary PK Parameters (Area under the plasma concentration-time curve from time 0 extrapolated to infinity(AUC0-∞))

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity(AUC0-∞)

    Time frame: 0 to 12 hours

  3. Secondary PK Parameters (Time to maximum (peak) plasma concentration(Tmax))

    Time to maximum (peak) plasma concentration(Tmax)

    Time frame: 0 to 12 hours

  4. Secondary PK Parameters (Terminal elimination rate constant(λz))

    Terminal elimination rate constant(λz)

    Time frame: 0 to 12 hours

  5. Secondary PK Parameters (Elimination half-life(t1/2))

    Elimination half-life(t1/2)

    Time frame: 0 to 12 hours

  6. Secondary PD Parameters (Area under the glucose infusion rate curve from time 0 to 2 hours(AUCGIR0-2h))

    Area under the glucose infusion rate curve from time 0 to 2 hours(AUCGIR0-2h)

    Time frame: 0 to 2 hours

  7. Secondary PD Parameters (Time to reach maximum glucose infusion rate(TGIRmax))

    Time to reach maximum glucose infusion rate(TGIRmax)

    Time frame: 0 to 12 hours

  8. Secondary PD Parameters (Time to onset of action,Tonset)

    Time to onset of action,Tonset

    Time frame: 0 to 12 hours

Other outcomes

  1. Immunogenicity Assessment (Anti-drug antibody (ADA) incidence (positive rate))

    Anti-drug antibody (ADA) incidence (positive rate)

    Time frame: 0 to 12 hours

  2. Immunogenicity Assessment (ADA titers (for positive samples))

    ADA titers (for positive samples)

    Time frame: 0 to 12 hours

07

Study locations

1 site
  • 28 Baofeng Road, Qiaokou District
    Wuhan, Hubei 430000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Nov 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 27, 2026
StartActual
Aug 4, 2025
Primary completionActual
Nov 25, 2025
CompletionActual
Jan 13, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07608692
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Aug 4, 2025
Primary completion
Nov 25, 2025
Completion
Jan 13, 2026
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion